Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344125 | 1.00 | DPP4 (0.42) | DPP4AAK1CTSSCTSKATM | |
| SCHEMBL30136576 | 1.00 | DPP4 (0.42) | DPP4AAK1CTSSCTSKATM | |
| SCHEMBL344599 | 0.94 | DPP4 (0.43) | DPP4AAK1CTSSCTSKATM | |
| SCHEMBL344600 | 0.94 | DPP4 (0.43) | DPP4AAK1CTSSCTSKATM | |
| SCHEMBL14982916 | 0.91 | REN (0.41) | DPP4AAK1CTSSCTSKREN | |
| SCHEMBL572252 | 0.91 | REN (0.41) | DPP4AAK1CTSSCTSKREN | |
| SCHEMBL8046225 | 0.91 | AAK1 (0.39) | DPP4AAK1CTSSCTSKATM | |
| SCHEMBL409962 | 0.89 | DPP4 (0.43) | DPP4AAK1CTSSCTSKATM | |
| SCHEMBL438365 | 0.89 | DPP4 (0.43) | DPP4AAK1CTSSCTSKATM | |
| SCHEMBL342707 | 0.89 | DPP4 (0.43) | DPP4AAK1CTSSCTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113636950-B | Preparation method of chiral 4-aryl-beta-amino acid derivative | 浙江医药股份有限公司新昌制药厂 | 2023-01-17 | — | — | CN | disclosed |
| CN-113636950-A | Preparation method of chiral 4-aryl-beta-amino acid derivative | 浙江医药股份有限公司新昌制药厂 | 2021-11-12 | — | — | CN | disclosed |
| US-9359385-B2 | Preparation of sitagliptin intermediates | LEK PHARMACEUTICALS D.D. (SI) | 2016-06-07 | — | — | US | disclosed |
| US-9359385-B2 | Preparation of sitagliptin intermediates | LEK PHARMACEUTICALS D.D. (SI) | 2016-06-07 | — | — | US | disclosed |
| EP-2669266-B1 | Improved Method for Manufacturing Dipeptidyl Peptidase-IV Inhibitor and Intermediate | DONG A ST CO LTD (KR) | 2016-02-24 | — | — | EP | disclosed |
| US-9174930-B2 | Preparation of sitagliptin intermediates | LEK PHARMACEUTICALS D.D. (SI) | 2015-11-03 | — | — | US | disclosed |
| US-9174930-B2 | Preparation of sitagliptin intermediates | LEK PHARMACEUTICALS D.D. (SI) | 2015-11-03 | — | — | US | disclosed |
| EP-2481722-B1 | SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2014-08-27 | — | — | EP | disclosed |
| US-20140213810-A1 | PREPARATION OF SITAGLIPTIN INTERMEDIATES | LEK PHARMACEUTICALS D.D. (SI) | 2014-07-31 | — | — | US | disclosed |
| US-20140213810-A1 | PREPARATION OF SITAGLIPTIN INTERMEDIATES | LEK PHARMACEUTICALS D.D. (SI) | 2014-07-31 | — | — | US | disclosed |
| US-8278486-B2 | Process and intermediates for the preparation of N-acylated-4-aryl beta-amino acid derivatives | CHIRAL QUEST, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2481722-A1 | SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
| US-20120178957-A1 | SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2012-07-12 | — | — | US | disclosed |
| EP-2423178-A1 | Process for the production of sitagliptin | Chemo Ibérica, S.A. (ES) | 2012-02-29 | — | — | EP | disclosed |
| EP-2415754-A2 | IMPROVED METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | Dong-A Pharmaceutical Co., Ltd. (KR) | 2012-02-08 | — | — | EP | disclosed |
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| US-20100280245-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST, INC. | 2010-11-04 | — | — | US | disclosed |
| US-20090192326-A1 | Preparation of sitagliptin intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-30 | — | — | US | disclosed |
| US-20090192326-A1 | Preparation of sitagliptin intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-30 | — | — | US | disclosed |
| WO-2009064476-A1 | PREPARATION OF SITAGLIPTIN INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192326-A1 | Preparation of sitagliptin intermediate | DPP4, DPP7, DPP3 | DPP4 1/4885AAK1 3415/4885CTSS 1611/4885 |
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | DPP4 1/4885AAK1 2836/4885CTSS 584/4885 |
| US-20120178957-A1 | SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF | DPP4, DPP8, DPP9 | DPP4 1/4885AAK1 2158/4885CTSS 2017/4885 |
| US-20100280245-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | NR4A3, GRIA3, NR2C2 | DPP4 3380/4885AAK1 3161/4885CTSS 4131/4885 |
| US-20140213810-A1 | PREPARATION OF SITAGLIPTIN INTERMEDIATES | DPP4, DPP3, DPP9 | DPP4 1/4885AAK1 2664/4885CTSS 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.